What In-House Manufacturing Means: From Active Ingredient to Sealed Vial

AKRO Research says its products are manufactured in its own lab in Orange County, California, where the active ingredient is prepared, filled, stoppered, freeze-dried, sealed and crimped. The lab is owned by JW Sciences, the company that also owns AKRO Research. Labelling and packaging also take place in Southern California. “In house” here means one operator runs each step from the active ingredient to the sealed vial, and the active ingredient itself, which is made in the USA, is not made in the lab. AKRO states that its products are made in the USA.

Which steps happen in the lab, and in what order?

The table follows the order in which AKRO describes its process. The second column says what each word means in plain terms, and the third says what AKRO states about the step.

Step	What the term means	What AKRO states
Active ingredient received	The active ingredient is the peptide material that ends up in the vial. It arrives at the lab already made.	Made in the USA. Not made in the lab.
Preparation	The lab’s own preparation of the active ingredient before it goes into vials.	Done in AKRO’s own lab in Orange County, California.
Vial cleaning and sterilization	Empty vials are cleaned, then sterilized, before they are filled.	Done in the same lab.
Filling	The prepared material is put into the vials.	Done in the same lab.
Stoppering	A rubber stopper is set in the neck of each filled vial.	Done in the same lab.
Lyophilization	Freeze-drying: the vials are frozen and the water is removed, leaving a dry powder.	Done in the same lab.
Crimping and sealing	A metal cap is crimped over the stopper and the vial is sealed.	Done in the same lab, after freeze-drying.
Labelling	Each vial receives its label.	Done in Southern California.
Packaging	Labeled vials are packed for shipping.	Done in Southern California.

Where does the active ingredient come from?

The active ingredient, the peptide material itself, is made in the USA and arrives at the lab already made. The lab does not build the molecule from raw chemicals. That is why AKRO says it manufactures the finished product, not the molecule: building the peptide molecule is a different stage of production, and AKRO does not claim to do it.

The difference matters to a buyer. A maker of the peptide molecule runs a chemical process that builds it one amino acid at a time. A supplier that manufactures the finished product starts from a molecule that has already been made. Both are real stages of production, but they are different claims, and they are easy to run together on a supplier page.

AKRO states that the active ingredient is made in the USA and that its products as a whole are made in the USA. The Orange County claim covers the lab, meaning the steps that start once the active ingredient arrives.

What does each step mean in plain terms?

Preparation and filling. In AKRO’s usage, preparation is the lab’s own work on the active ingredient before it goes into vials, and filling puts the prepared material into the vials. This page does not describe the method, equipment or conditions used for either step.

Vial cleaning, sterilization and stoppering. Vials are cleaned and sterilized before they are filled, and a rubber stopper is set in the neck of each one after filling. A clean, sterile vial matters because anything left on its inner surface would end up in the contents.

Lyophilization. Lyophilization is freeze-drying. A published description of the process divides it into three steps: freezing, primary drying and secondary drying (PMID 37783925). In primary drying the ice leaves as vapor under reduced pressure, and in secondary drying the remaining bound water is removed. What is left is a dry powder, and AKRO describes its product form as lyophilized (freeze-dried) powder in sealed vials, and each lot is tested for sterility.

Crimping, sealing and labelling. After freeze-drying, a metal cap is crimped over each stopper and the vial is sealed in the same lab. Labelling and packaging follow, also in Southern California.

How is in-house different from reselling?

A reseller buys finished vials and passes them on, sometimes under its own label. A supplier that fills and seals its own vials performs those steps itself. Between the two sit other arrangements: buying bulk material and having another firm fill it, or buying finished vials and relabeling them. Each can be described honestly. What matters to a buyer is whether the description says which step happened where.

AKRO’s description is that the steps from preparation to crimping take place in one lab in Orange County, California, owned by the same company that owns AKRO Research, with labelling and packaging also in Southern California.

What is a lot, and what does lot traceability add?

A lot, also called a batch, is a defined quantity of product made in one production run. Lot traceability means that any vial can be tied back to its lot and to the records kept for that lot. If a question arises about one vial, the lot’s records are where the answer is kept.

AKRO states that each lot is tested by an outside third-party laboratory on an extended panel: identity, purity, content (how much peptide is in the vial), endotoxin, sterility and heavy metals, with further tests added when they become available. It states that every product tests above 99% purity by HPLC (a lab method for measuring purity). Each lot has its own certificate of analysis (the lab’s report on that lot), and each certificate names the laboratory that ran the tests. AKRO publishes the certificates: the QR code on each vial opens a page with the latest certificate of analysis for that product, and the certificate for an earlier lot can be found by its lot number.

How to read that certificate is covered in How to read a peptide certificate of analysis, and what the two tests measure is covered in HPLC vs mass spectrometry for peptides.

How can a buyer check any in-house claim?

These questions work for any supplier, and the reason for each is given with it.

• Which steps happen at the supplier’s own site, and which are done by someone else? A supplier can fill and seal vials itself while buying bulk material, or it can buy sealed vials and add only a label. These are very different claims, and both can be called “in house” by a careless writer.
• Who owns the facility, and in which country does each step take place? A named operating company and a named country can be checked. A general phrase cannot.
• Can the supplier describe the steps in order, in its own words? A real process has an order, and a supplier that runs it can usually say what comes before and after each step.
• Does the vial carry a lot number that matches a lot-specific certificate of analysis? The number on the vial, the number on the certificate and the number in the supplier’s records should all agree. How to read a peptide certificate of analysis explains the matching.
• Is the claim to manufacture the finished product, or to make the peptide molecule itself? These are different claims, so ask which one is meant.
• Does the wording stay specific? A general origin phrase says little until it names which step took place where.

What does in-house not tell you?

In-house describes who performs the steps. It is not a quality rating, and it does not say how well the steps are done. That is the job of testing and of the certificate of analysis for each lot. It also does not say where the active ingredient was made, and it does not make one lot the same as another, which is why each lot is documented and tested on its own.

Related guides

• How to Verify Any Peptide Supplier: A Buyer Checklist
• Why lot traceability matters for research peptides

Last reviewed: 2026-10-20

References

• Practical Advice on Scientific Design of Freeze-Drying Process: 2023 Update. Pharm Res. 2023. PMID: 37783925